BioSpace News Archive

Currax Pharmaceuticals LLC (“Currax”) today announced top-line results from a Cardiovascular Health Outcomes Analysis (HOA).

Tonix Pharmaceuticals Holding Corp. today announced that a study published in the Journal Nature1 by faculty at the Center for Transplantation Sciences, Massachusetts General Hospital (MGH) in collaboration with biotechnology company, eGenesis, utilized TNX-1500 (Fc-modified dimeric anti-CD40L monoclonal antibody [mAb]) as part of the immune modulating regimen to prevent organ transplant rejection.

RayzeBio, Inc. today announced that it will be presenting interim safety and efficacy data from the Phase 1b portion of the ACTION-1 Trial for RYZ101 (Ac225 DOTATATE) at the upcoming European Society of Medical Oncology (ESMO) Congress, being held in Madrid between 20-24 October 2023.

Axogen, Inc. today announced that it will report third quarter 2023 financial results on Tuesday, November 7, 2023 before the market opens.

Bolt Biotherapeutics (Nasdaq: BOLT), a clinical-stage biopharmaceutical company developing novel immunotherapies for the treatment of cancer, today announced that it will present four posters at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting.

CervoMed Inc. (NASDAQ: CRVO) today announced it will present deeper insights highlighting the neflamapimod clinical development program, including findings in phase2a that led to the final Phase 2b study design for the treatment of patients with dementia with Lewy bodies (DLB), in an oral presentation at the 16th Clinical Trials in Alzheimer’s Disease (CTAD) conference, being held October 24-27, 2023, in Boston, Massachusetts.

Cessation Therapeutics, Inc. today announced that it has been awarded an additional grant from the National Institute on Drug Abuse (NIDA, a division of the National Institutes of Health).

Oxford BioDynamics, Plc, a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform and Bupa, the UK’s leading health insurer, announce a strategic agreement to give Bupa patients access to OBD’s EpiSwitch CiRT.

AN2 Therapeutics, Inc. today announced that it has received an exclusive license from the University of Georgia Research Foundation to advance the development of a boron-containing small molecule for Chagas disease.

Broken String Biosciences, a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design, announced that its INDUCE-seq™ DNA break-mapping technology had been used in a peer-reviewed research paper to characterize off-target effects of CRISPR-Cas9 gene editing resulting from changes in DNA topology.